{"id":"https://openalex.org/W2133520792","doi":"https://doi.org/10.1158/1078-0432.ccr-11-1209","title":"Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor","display_name":"Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor","alternate_titles":[],"publication_year":2011,"publication_date":"2011-09-14","ids":{"openalex":"https://openalex.org/W2133520792","doi":"https://doi.org/10.1158/1078-0432.ccr-11-1209","mag":"2133520792","pmid":"https://pubmed.ncbi.nlm.nih.gov/21825041"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-11-1209","doi":"https://doi.org/10.1158/1078-0432.ccr-11-1209","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-11-1209","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2133520792"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013825576","display_name":"Niels J\u00f8rgen \u00d8stergaard Skartved","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Niels J\u00f8rgen \u00d8stergaard Skartved","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114045543","display_name":"Helle Jane Jacobsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Helle Jane Jacobsen","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051105658","display_name":"Mikkel Wandahl Pedersen","orcid":"https://orcid.org/0000-0001-5711-9051","observed_orcids":["https://orcid.org/0000-0001-5711-9051"]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mikkel Wandahl Pedersen","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078468771","display_name":"Pernille Foged Jensen","orcid":"https://orcid.org/0000-0003-1495-6110","observed_orcids":["https://orcid.org/0000-0003-1495-6110"]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pernille Foged Jensen","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059566009","display_name":"Jette Wagtberg Sen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jette Wagtberg Sen","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004786489","display_name":"Thomas Kj\u00e6rsgaard J\u00f8rgensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas Kj\u00e6rsgaard J\u00f8rgensen","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029550004","display_name":"Adam Hey","orcid":"https://orcid.org/0000-0002-8982-3219","observed_orcids":["https://orcid.org/0000-0002-8982-3219"]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Adam Hey","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111779564","display_name":"Michael Kragh","orcid":"https://orcid.org/0000-0002-8360-3514","observed_orcids":["https://orcid.org/0000-0002-8360-3514"]},"institutions":[{"id":"https://openalex.org/I4210088995","display_name":"Symphogen (Denmark)","ror":"https://ror.org/008kt5750","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210088995"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Kragh","raw_affiliation_strings":["Authors' Affiliation: Symphogen A/S, Lyngby, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Symphogen A/S, Lyngby, Denmark","institution_ids":["https://openalex.org/I4210088995"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210088995"],"apc_list":null,"apc_paid":null,"fwci":1.929,"has_fulltext":false,"cited_by_count":41,"citation_normalized_percentile":{"value":0.84639876,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"17","issue":"18","first_page":"5962","last_page":"5972"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.5990999937057495,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.5990999937057495,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.31540000438690186,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.018799999728798866,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.9480000138282776},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8659999966621399},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8510000109672546},{"id":"https://openalex.org/keywords/preclinical-safety-evaluation","display_name":"preclinical safety","score":0.7670000195503235},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.7009999752044678},{"id":"https://openalex.org/keywords/repeated-dose-toxicity","display_name":"repeated-dose toxicity","score":0.718999981880188},{"id":"https://openalex.org/keywords/cynomolgus-monkeys","display_name":"Macaca fascicularis","score":0.8399999737739563},{"id":"https://openalex.org/keywords/mouse-xenograft-model","display_name":"xenograft mouse model","score":0.7509999871253967},{"id":"https://openalex.org/keywords/antibody-accumulation","display_name":"antibody accumulation","score":0.5149999856948853},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.4440000057220459}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9030265808105469},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.728534460067749},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6826416850090027},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6492472887039185},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6278674602508545},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6152851581573486},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.550334095954895},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5134371519088745},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.46280354261398315},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.448047012090683},{"id":"https://openalex.org/C2776362946","wikidata":"https://www.wikidata.org/wiki/Q424374","display_name":"Epidermal growth factor","level":3,"score":0.4120199382305145},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3951282501220703},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3444725275039673},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.32358214259147644},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26163482666015625}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000888","descriptor_name":"Antibodies, Anti-Idiotypic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D003429","descriptor_name":"Cross Reactions","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006168","descriptor_name":"Guinea Pigs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008252","descriptor_name":"Macaca fascicularis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011817","descriptor_name":"Rabbits","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-11-1209","doi":"https://doi.org/10.1158/1078-0432.ccr-11-1209","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-11-1209","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:21825041","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21825041","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1967295501","https://openalex.org/W1988962161","https://openalex.org/W1991671417","https://openalex.org/W2000436105","https://openalex.org/W2002058320","https://openalex.org/W2008716770","https://openalex.org/W2011513069","https://openalex.org/W2034287995","https://openalex.org/W2039633811","https://openalex.org/W2039950956","https://openalex.org/W2040756306","https://openalex.org/W2046877602","https://openalex.org/W2068125497","https://openalex.org/W2070767967","https://openalex.org/W2074404879","https://openalex.org/W2101299592","https://openalex.org/W2104239861","https://openalex.org/W2134989772","https://openalex.org/W2137950260","https://openalex.org/W2139470111","https://openalex.org/W2155284019","https://openalex.org/W2161482321"],"related_works":["https://openalex.org/W2316017940","https://openalex.org/W2590114812","https://openalex.org/W2885504314","https://openalex.org/W2669578524","https://openalex.org/W1914403651","https://openalex.org/W2137950260","https://openalex.org/W1997681258","https://openalex.org/W2566276902","https://openalex.org/W2564982514","https://openalex.org/W2327093983"],"abstract_inverted_index":{"PURPOSE:":[0],"Sym004":[1,27,73,82,101,124,136,157,182,233],"is":[2],"a":[3,86,138],"novel":[4,189],"therapeutic":[5],"antibody":[6],"mixture":[7],"product":[8],"comprising":[9,123,230],"two":[10],"unmarketed":[11],"monoclonal":[12],"antibodies":[13,122,170,229],"(mAb)":[14],"targeting":[15],"the":[16,46,51,103,120,128,168,193,227,251],"epidermal":[17],"growth":[18,35],"factor":[19],"receptor":[20],"(EGFR).":[21],"In":[22,177],"previous":[23],"preclinical":[24,52,245],"proof-of-concept":[25],"studies,":[26],"was":[28,215,234],"shown":[29],"to":[30,56,74,106,111,142,158],"elicit":[31],"superior":[32],"cancer":[33],"cell":[34],"inhibition":[36],"activities":[37],"compared":[38],"with":[39,72,180,226],"marketed":[40,116],"anti-EGFR":[41,117],"mAbs.":[42],"This":[43],"article":[44],"describes":[45],"design":[47],"and":[48,90,119,150,175,202,212,237],"results":[49],"of":[50,61,81,100,156,167,199,250],"safety":[53,246],"program":[54],"conducted":[55],"support":[57],"early":[58,197],"clinical":[59,253],"development":[60],"Sym004.":[62,231],"EXPERIMENTAL":[63],"DESIGN:":[64],"Tissue":[65],"cryosections":[66],"from":[67,147],"various":[68],"species":[69],"were":[70,83,125,221],"stained":[71],"evaluate":[75],"tissue":[76,145],"cross":[77],"reactivity.":[78],"The":[79,244],"pharmacokinetics":[80],"evaluated":[84],"in":[85,91,102,127,144,172,192,223],"mouse":[87],"xenograft":[88],"model":[89],"Cynomolgus":[92,159],"monkeys.":[93],"Monkeys":[94],"received":[95],"once":[96],"weekly":[97,154],"intravenous":[98],"infusions":[99],"range":[104],"2":[105],"24":[107],"mg/kg":[108],"for":[109],"6":[110],"8":[112],"weeks.":[113],"Cetuximab":[114],"(a":[115],"mAb)":[118],"individual":[121,169,228],"included":[126],"repeat-dose":[129],"toxicity":[130],"studies":[131],"at":[132],"single-dose":[133],"level.":[134],"RESULTS:":[135],"had":[137],"staining":[139],"pattern":[140],"similar":[141],"cetuximab":[143],"panels":[146],"both":[148],"human":[149],"non-human":[151],"primates.":[152],"Once":[153],"dosing":[155],"monkeys":[160],"did":[161,183,238],"not":[162,184,239],"cause":[163],"accumulation,":[164],"whereas":[165],"administration":[166],"resulted":[171],"prolonged":[173],"half-life":[174],"accumulation.":[176],"direct":[178],"comparisons":[179],"cetuximab,":[181],"induce":[185,240],"any":[186,241],"distinct":[187],"or":[188],"adverse":[190,219],"findings":[191],"animals.":[194],"However,":[195],"an":[196],"onset":[198],"pronounced,":[200],"reversible,":[201],"anticipated":[203],"anti-EGFR-mediated":[204],"pharmacologic":[205],"effects,":[206],"such":[207],"as":[208],"skin":[209],"rash,":[210],"dehydration,":[211],"liquid":[213],"feces,":[214],"observed.":[216],"Only":[217],"minor":[218],"effects":[220],"recorded":[222],"animals":[224],"treated":[225],"CONCLUSION:":[232],"well":[235],"tolerated":[236],"unexpected":[242],"toxicities.":[243],"data":[247],"enabled":[248],"initiation":[249],"ongoing":[252],"development.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2133520792","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
